Recent developments in 3D printing pharmaceutical, bioprinting and implant for tissue engineering formulations.

IF 3.6 4区 医学 Q2 ENGINEERING, BIOMEDICAL
Ranjitsinh Pawar, Ankeeta Sankapall, Mayur Samal, Vaishnavi Sadaphal, Sabeeha Mohiudin, Mangesh Sangale
{"title":"Recent developments in 3D printing pharmaceutical, bioprinting and implant for tissue engineering formulations.","authors":"Ranjitsinh Pawar, Ankeeta Sankapall, Mayur Samal, Vaishnavi Sadaphal, Sabeeha Mohiudin, Mangesh Sangale","doi":"10.1080/09205063.2025.2505350","DOIUrl":null,"url":null,"abstract":"<p><p>This review article explores how 3D printing has the diversity in the drug development and the delivery of personalized medicine. The paradigm shift is from conventional methods to tailormade dosages and exploring the intricate interplay of drug selection, polymer compatibility alongwith technological advancements within the pharmaceutical arena. 3D printing is positioned as a crucial tool for catering to the specific requirements of patient-focused fields like pediatrics and geriatrics, ranging from addressing individual needs to improving dosage precision. By harnessing genetic profiles, physiological nuances, and disease conditions, this technology enables the creation of bespoke medications with unique drug loading and release profiles. In developing the newer implants the 3D printing has to be developed alongwith consideration of biological aspects as well as technical aspects. It has to be aligned with multifunctional aspects to cater one optimized product. Furthermore, this paper elucidates the regulatory considerations and industrial implications surrounding 3D printing in pharmaceuticals. Emphasizing compliance with current Good Manufacturing Practices (CGMP) and its potential for streamlined production in regulated markets, the paper underscores the transformative power of 3D printing in reshaping clinical practice and optimizing patient outcomes.</p>","PeriodicalId":15195,"journal":{"name":"Journal of Biomaterials Science, Polymer Edition","volume":" ","pages":"1-48"},"PeriodicalIF":3.6000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomaterials Science, Polymer Edition","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/09205063.2025.2505350","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

This review article explores how 3D printing has the diversity in the drug development and the delivery of personalized medicine. The paradigm shift is from conventional methods to tailormade dosages and exploring the intricate interplay of drug selection, polymer compatibility alongwith technological advancements within the pharmaceutical arena. 3D printing is positioned as a crucial tool for catering to the specific requirements of patient-focused fields like pediatrics and geriatrics, ranging from addressing individual needs to improving dosage precision. By harnessing genetic profiles, physiological nuances, and disease conditions, this technology enables the creation of bespoke medications with unique drug loading and release profiles. In developing the newer implants the 3D printing has to be developed alongwith consideration of biological aspects as well as technical aspects. It has to be aligned with multifunctional aspects to cater one optimized product. Furthermore, this paper elucidates the regulatory considerations and industrial implications surrounding 3D printing in pharmaceuticals. Emphasizing compliance with current Good Manufacturing Practices (CGMP) and its potential for streamlined production in regulated markets, the paper underscores the transformative power of 3D printing in reshaping clinical practice and optimizing patient outcomes.

最近在3D打印制药,生物打印和植入组织工程配方的发展。
这篇综述文章探讨了3D打印如何在药物开发和个性化医疗交付方面具有多样性。范式的转变是从传统方法到量身定制的剂量,并探索药物选择、聚合物相容性以及制药领域的技术进步之间复杂的相互作用。3D打印被定位为满足以患者为中心的领域(如儿科和老年医学)的特定要求的关键工具,从解决个人需求到提高剂量精度。通过利用基因图谱、生理细微差别和疾病状况,这项技术能够创造出具有独特药物装载和释放图谱的定制药物。在开发新的植入物时,3D打印必须与生物方面以及技术方面的考虑一起开发。它必须与多功能方面保持一致,以迎合一个优化的产品。此外,本文阐明了药品中3D打印的监管考虑和工业影响。本文强调符合现行的良好生产规范(CGMP)及其在监管市场中简化生产的潜力,强调了3D打印在重塑临床实践和优化患者结果方面的变革力量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biomaterials Science, Polymer Edition
Journal of Biomaterials Science, Polymer Edition 工程技术-材料科学:生物材料
CiteScore
7.10
自引率
5.60%
发文量
117
审稿时长
1.5 months
期刊介绍: The Journal of Biomaterials Science, Polymer Edition publishes fundamental research on the properties of polymeric biomaterials and the mechanisms of interaction between such biomaterials and living organisms, with special emphasis on the molecular and cellular levels. The scope of the journal includes polymers for drug delivery, tissue engineering, large molecules in living organisms like DNA, proteins and more. As such, the Journal of Biomaterials Science, Polymer Edition combines biomaterials applications in biomedical, pharmaceutical and biological fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信